Compare ADV & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADV | CTNM |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | 73000 | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 550.7M |
| IPO Year | N/A | 2024 |
| Metric | ADV | CTNM |
|---|---|---|
| Price | $36.78 | $14.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.83 | $19.00 |
| AVG Volume (30 Days) | 158.6K | ★ 459.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.63 | N/A |
| Revenue Next Year | $0.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $5.08 |
| 52 Week High | $47.45 | $16.91 |
| Indicator | ADV | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 49.37 |
| Support Level | $36.65 | $13.62 |
| Resistance Level | $42.30 | $14.73 |
| Average True Range (ATR) | 2.63 | 0.92 |
| MACD | -0.65 | -0.14 |
| Stochastic Oscillator | 41.35 | 24.95 |
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.